ReviewResearch (Washington, D.C.)2025
Lysosome-Iron-Mitochondria Axis in Osteoclasts: Iron as a Central Player.
Review in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Bone organoids and mitochondrial reprogramming.Journal of orthopaedic translation · 2026Review
- Temporal transcriptomic profiling uncovers multilevel suppression of RANKL-driven osteoclast differentiation by 14-3-3ζ.The Journal of biological chemistry · 2026Article
- Natural Polysaccharide-Mediated Nano-Delivery Systems for Osteoporosis Therapy From a Gut-Bone Axis Regulatory Perspective.Advanced healthcare materials · 2026Review
- SGLT2 Inhibitors: Dual Effects on Erythropoiesis and Bone Metabolism.Journal of bone metabolism · 2026Review
- Breaking the immune "cold niche" in bone metastasis: core mechanisms of the multidimensional interwoven regulatory network and precision breakthrough strategies.Molecular cancer · 2026Review
- Promoting Bone Health in Layer Chickens from the Perspective of Mitochondrial Energy Metabolism in Osteoclasts.Animals : an open access journal from MDPI · 2026Review
- The Multilayered Landscape of Ferroptosis: Plasticity, Propagation, and Evolutionary Perspectives.Antioxidants (Basel, Switzerland) · 2026Review
- Hemochromatosis osteoarthritis.Frontiers in endocrinology · 2026Review
- Circadian regulation of osteoclast lysosomal-resorption machinery: implications for osteoporosis therapy.Frontiers in cell and developmental biology · 2026Review
- PEDOTs in Bone Tissue Engineering Composites: Fabrication Strategies and Translational Hurdles.Research (Washington, D.C.) · 2026Review
- Lycopene Alleviates Deoxynivalenol-Induced Porcine Intestinal Epithelial Barrier Injury by Inhibiting PGAM5-Mediated Mitophagy-Dependent Ferroptosis.Research (Washington, D.C.) · 2026Article
- Bidirectional crosstalk between the bone extracellular matrix and lysosomes in bone remodeling and osteoporosis.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis, a widespread skeletal disorder, arises from excessive bone loss, heightening fragility and fracture risk. Osteoclasts, the major type of bone-resorbing cells, are believed to contribute to this loss. Osteoclast bone resorption relies on 2 important organelles: lysosomes for matrix degradation and mitochondria for energy supply. Iron, a critical linker between lysosomes and mitochondria, has emerged as a critical mediator of osteoclast activity. However, the intricate interplay between lysosomes, mitochondria, and iron in osteoclasts and osteoporosis remains poorly understood. This review aims to bridge this knowledge gap by examining the lysosome-iron-mitochondria axis in osteoclasts. Firstly, we summarized the modulatory function of lysosomes in iron metabolism and iron's involvement in lysosomal biogenesis and function. Next, we conducted a comprehensive analysis on the contribution of iron in mitochondrial function and its implications for osteoclast activity. Subsequently, we highlighted emerging insights into the lysosome-mitochondria crosstalk in iron metabolism. Finally, we delved into the discussion of how dysregulation of this lysosome-iron-mitochondria axis may drive osteoporosis progression and proposed innovative therapeutic strategies targeting this axis to mitigate osteoclast-mediated bone loss.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.